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Summary
This study was designed to examine whether the apoptotic-inhibitor sFas and the apoptotic inducer FasL are differen-
tially present in two opposite phenotypes of autoimmune thyroid disorders (AITD) and nodular goiter (NG). Methods: 
sFas and FasL levels were determined using ELISA in the serum sample of a total 70 patients with thyroid disorders. 
Fas-mediated apoptosis plays an important role in the active stage of the autoimmune process of both GD and HT. Incre-
ased sFas in GD and FasL in HT may contribute to homeostasis in thyroid gland. In NG, however, sFas and FasL may 
provide a key protective signal that helps the cells to avoid apoptosis in a hostile environment.
Key words: autoimmune thyroid disease, Fas ligand, soluble Fas, Graves’ disease, Hashimoto’s thyroiditis, nodular 
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Rezumat. Fas solubil şi ligandul fas în patogeneza bolilor tiroidiene autoimune
Acest studiu a fost proiectat pentru a examina inhibarea apoptozei a formei solubile de FasL (sFasL) şi inductor apop-
totic al FasL, care sunt prezente în mod diferenţiat în cele două fenotipuri opuse ale bolii autoimune tiroidiene (AITD) 
şi guşă nodulară (GN). Metode: nivelurile sFasL şi FasL au fost calculate prin intermediul ELISA în proba de ser pentru 
un total de 70 de pacienţi cu bolile tiroidiene. Apoptoza Fas-mediată joacă un rol important în faza activă a procesului 
autoimun cum în tiroidita Hashimoto (TH), aşa şi în boala Graves (BG). Nivelurile crescute de sFasL la BG şi FasL în 
TH poate ajuta la normalizarea homeostaziei tiroidiene. Cu toate acestea, pacienţilor cu GN, sFasL şi FasL poate furniza 
semnal cheie de securitate, care ajută la prevenirea celule tiroidiene apoptoza în prezenţa celulelor maligne.
Cuvinte-cheie: boli tiroidiene autoimune, Fas ligand, solubil Fas, boala Graves, tiroidita Hashimoto, guşă nodulară
Резюме. Растворимая fas и fas-лиганда в патогенезе аутоиммунных заболеваний щитовидной железы
Данное исследование было разработано с целью изучения вопроса апоптической ингибиции растворимой 
формой FasL (sFasL) и апоптическим индуктором FasL, которые дифференциально присутствуют в двух проти-
воположных фенотипах аутоиммунных заболеваний щитовидной железы (АИЩЗ) и узлового зоба (УЗ). Методы: 
концентрацию sFasL и FasL определяли с помощью ELISA в образце сыворотки в общей сложности у 70 паци-
ентов с патологией щитовидной железы. Fas – опосредованный апоптоз играет важную роль в активной стадии 
аутоиммунного процесса как при тиреоидите Хашимото (ТХ), так и при болезни Грейвса (БГ). Увеличение уровня 
sFasL при БГ и FasL при ТХ может способствовать нормализации гомеостаза в щитовидной железе. Однако, при 
узловом зобе, sFasL и FasL может обеспечить ключевой защитный сигнал, который помогает клеткам щитовид-
ной железы избежать апоптоз в присутствии злокачественных клеток.
Ключевые слова: аутоиммунные заболевания щитовидной железы, Fas-лиганда, растворимый Fas, болезнь 
Грейвса, тиреоидит Хашимото, узловой зоб
_______________________________________________________________________________________________
Introduction
The main place in the structure of endocrine di-
seases belongs to the thyroid gland (TG). In Ukraine 
it reached 46.67% as of 01.01.2011 [1]. This is due on 
the one hand environmental degradation in the coun-
try, increasing stressful of social origin, on the other 
improved diagnosis of this disease. Despite the fact 
that the study of thyroid disease, always given due 
attention by leading thyroid specialists in the world, 
this issue is very relevant and requires further study.
The autoimmune attack on the thyroid results 
in two opposing clinical syndromes -Hashimoto’s 
thyroiditis and Graves’ disease. In HT the lympho-
cytic infi ltration of the thyroid gland leads to apopto-
sis of thyroid cells and hypothyroidism [6,7,9,17,27]. 
In contrast, in GD the lymphocytic infi ltration of the 
thyroid leads to activation of thyrotropin receptor 
(TSHR) – reactive B-cells that secrete TSHR-stimula-
ting antibodies causing hyperthyroidism [13,22]. The 
etiology of HT and GD involves common pathways 
in which thyroid reactive T-cells escape tolerance and 
infi ltrate the thyroid, and unique pathways in which 
the thyroid-reactive T-cells either cause thyroid cell 
death (in HT) or stimulation (in GD). Thus, it is not 
surprising that the genetic susceptibility to HT and 
GD involves shared genes, as well as unique genes 
[9,24,30]. The processes involved in apoptosis are ti-
ghtly regulated. Alterations in their functioning may 
result in disorders such as autoimmune diseases and 
cancer [4].
Apoptosis may play an important role in the ho-
meostasis of thyroid follicular cells as well as de-
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structive mechanisms in thyroid disease. Apoptosis 
is a mechanism by which cytotoxic T-lymphocytes 
can destroy thyrocytes in thyroiditis, leading in turn 
to hypothyroidism [18,25]. In contrast, the suppressi-
on of apoptosis may contribute to proliferative disea-
ses of the thyroid gland, such as goiter, cancer, and 
GD [1,2,4,10,11]. However, little is known about the 
mechanisms and regulation of apoptotic signaling in 
thyroid cells. It is important to defi ne the signaling 
components of apoptosis in thyroid follicular cells. 
These signaling components may help in providing 
insights into potential pathogenic mechanism and 
lead to development of pharmacological interventi-
ons for the treatment of thyroid disease [1,3,19,28].
One of the best characterized death receptors is 
Fas known as CD95/APO-1/TNFRSF6. It is a 36 
KDa cell surface type-1 membrane glycoprotein. Fas 
ligand (FasL) is a type-II transmembrane protein of 
the same family, which has the ability to bind Fas 
[5,14,20]. Fas has been shown to be an important me-
diator of apoptotic cell death. It is also involved in 
infl ammation. Binding of FasL induces trimerization 
of Fas in the target cell membrane. Activation of Fas 
causes the recruitment of Fas associated protein with 
death domain (FADD) via interactions between the 
death domain of Fas and FADD. 
Fas can occur both as a cell surface protein and 
a soluble protein. Cell surface Fas is anchored by a 
single membrane-spanning domain and is widely ex-
pressed in normal and malignant cells [1,2,8,21].  So-
luble Fas (sFas), alternatively spliced Fas mRNA that 
results from deletion of exons 3, 4, 6 & 7 and lacks 
21 amino acid residues that contain a transmembrane 
domain. sFas protects target cells from Fas-induced 
apoptosis by competitively binding with FasL and 
altering lymphocyte development and proliferati-
on in response to self antigens [2,8,23,26]. The Fas 
pathway has been demonstrated to be the important 
apoptotic pathway in the thyroid gland. Its role in the 
pathogenesis of thyroid diseases, however, is contro-
versial and a subject of much debate [26,29]. Regula-
tion or modulation of this pathway can occur at mul-
tiple levels throughout the pathway. This may include 
changes in the level of the expression of Fas or its 
ligand [8,11]; regulation of components of intracellu-
lar signaling) [1,3,19,28] and expression of proteins 
that promote survival, such as members of the Bcl-2 
gene family) [15,16].
This study summarizes the role of Fas-mediated 
apoptosis in thyroid diseases such as goiter, thyroid 
cancer, and autoimmune thyroid diseases. In addition, 
markers of humoral immune response (thyroglobulin 
and thyroid peroxidase antibodies) were also evalua-
ted to compare with sFas and FasL levels.
Materials and Method. A total of 70 patients 
with thyroid disorder (age range: 07-to-78 years) 
were enrolled in the current study. All the patients 
were newly diagnosed and untreated for their conditi-
on at the time of blood collection. Also, due and requ-
ired consent was taken from each patient to enroll in 
this study prior to blood collection. The study was 
approved by Institutional Scientifi c Review Board & 
Ethics Committee. The diagnosis of GD and HT was 
based on commonly accepted clinical and laboratory 
criteria. In case of NG, blood samples collected prior 
to surgery and diagnosis was based on histopatho-
logical investigation. Of all 70 patients, 47 (67.1%) 
had AITD, and 23 (32.9%) had NG. For comparison 
with patients, 20 age matched, healthy individuals 
were included. They had normal thyroid function test 
results, no goiter, and were negative for antithyriod 
autoantibodies. Venous blood samples were collected 
in Vacutainer tubes between 9:00 to 11:00 am. The 
samples were allowed to clot for 30 minutes at room 
temperature. Sera were obtained by centrifugation, 
were aliquoted, and stored at -20°C till analysis. All 
the samples were analyzed for thyroid hormone leve-
ls and thyroid autoantibodies.
Evaluation of Soluble Fas and Fas Ligand. 
Circulating sFas and FasL were estimated using 
sandwich ELISA (Quantikine, R&D systems, USA) 
kits. Sample activation and dilution were performed 
according to the manufacturer’s protocol. The unit of 
measure for the levels of sFas and FasL was ng/mL. 
The detection range was 0-2.0 ng/mL and 0-1.0 ng/
mL for sFas and FasL, respectively. All enzymatic re-
action products were determined photometrically at 
450 nm by Plate reader (Thermolabsystems, Finland; 
Multiskan spectrum).
Evaluation of Thyroid Autoantibodies. Com-
mercially available kits (Immunotech, France) were 
used for the measurement of serum anti-thyroglobu-
lin (anti-TG), and anti-thyroid peroxidase (anti-TPO) 
antibodies with the automated gamma counter (Pac-
kard, cobra). The detection range was 0-to-250.0 ng /
mL and 0-2100.0 IU /mL for TG and TPO, respecti-
vely. Measurements were based on radioimmunoas-
say and immunoradiomatric assay.
Statistical Analysis. All the statistical analysis 
carried out with the SPSS 17.0 software and statisti-
cal signifi cance was computed using students’ t-test 
and ANOVA. Receiver’s operating characteristic 
(ROC) curve was also constructed to determine the 
discriminating effi cacy of sFas and FasL. p< 0.05 was 
considered as a statistically signifi cant. The correla-
tion of TPO and TG with sFas and FasL was done 
by parametric analysis, i.e. Pearson’s correlation and 
non-parametric, i.e. Spearman’s correlation test. 
177Științe Medicale
Results. A total of 70 samples and 20 controls 
were analyzed for sFas and FasL levels. Higher mean 
levels of sFas and FasL observed in thyroid diseases 
were statistically signifi cant when compared with 
controls. The results of circulating serum sFas and 
FasL levels in the examined thyroid disease patients 
are shown in Table 1 as mean ± standard error of the 
mean in ng/mL.
Levels of sFas were higher in all the studied 
groups as compared to the controls. However, the hi-
ghly signifi cant values were found in GD patients as 
compared to controls (0.802 ± 0.059vs 0.589 ± 0.014, 
p = 0.0001) and compared to HT (0.802 ± 0.059 
vs0.629 ± 0.039, p = 0.068). 
Table 1 
Signifi cance of Soluble Fas and Fas ligand levels 




Mean ± S.E. (ng/
mL)
Fas ligand
Mean ± S.E. 
(ng/mL)



















The difference in FasL levels between GD (0.058 
± 0.003) and HT (0.063 ± 0.007) was not signifi cant.
Signifi cantly higher levels of FasL were observed 
for NG patients compared to controls (0.061 ± 0.005 
vs0.041 ± 0.006, p = 0.003).
Table 2 
Levels of thyroid peroxidase and thyroglobulin in 




Mean ± S.E. 
(IU/mL)
Thyroglobulin
Mean ± S.E. 
(ng/mL)



















Levels of TPO and TG antibodies were also mea-
sured and found higher in all groups except TG in the 
HT group (Table 2). Parametric and nonparametric 
correlation tests showed signifi cant linear correlati-
ons between sFas and TG (r = 0.319, p =0.05), TPO 
(r = 0.384, p = 0.019). Signifi cant linear correlations 
were also found between sFas andTPO antibodies 
(r = 0.590, p = 0.021) in HT patients and between 
sFas and TG (r = 0.543, p =0.011) in NG patients. 
There was no correlation between FasL and TG 
or TPO ROC curve indicates that both sFas and FasL 
exhibited a good discriminatory effi cacy between 
controls and GD patients (sFas: AUC-0.856; FasL: 
AUC-0.801) (Figure 1).
Discussion. The control of thyroid gland volu-
me results from an equilibrium between the trophic 
action of TSH and thyrocyte apoptosis. Apoptosis is 
limited to some extent by resistance to Fas activati-
on by production of an inhibitor of apoptotic signal 
transduction [1,3,19,28]. In the Fas/FasL apoptotic 
Fig. 1. ROC curve for Soluble Fas (red line) and Fas ligand (blue line) between Graves’s disease 
patients with controls †
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pathway, Fas, FasL and sFasL are thought to induce 
apoptosis while sFas inhibits apoptosis. The current 
prospective study was designed to examine whether 
sFas, an inhibitor of apoptosis, and FasL, an inducer 
of apoptosis are differentially present in two opposite 
phenotypes of autoimmune thyroid disorders and no-
dular goiter.
In the study, all patients with various thyroid di-
seases showed elevated levels of sFas. However, the 
highest concentrations were found in patients with 
AITD. Hiromatsu et al. demonstrated Fas expressed 
in cell membranes and predisposed to FasL mediated 
apoptosis. Fas may be present both on the thyrocytes 
of patients with AITD with infi ltrating lymphocytes 
[1,6,17,18].
Moreover, we found higher levels of sFas in GD 
patients. This fi nding concurs with the study result of 
Hiromatsu et al. [15]. They have demonstrated that 
increased sFas in GD suggest increased expression of 
an alternatively spliced mRNA variant that produces 
sFas proteins that decreases the cell expression of Fas 
and may induce thyroid cell growth and production of 
TSH receptor antibodies by protecting against apop-
tosis of thyroid cells.
Fountolakis et al. have also demonstrated that 
elevated sFas in GD may refl ect reduced full length 
membrane Fas and may have a role in the inhibition 
of Fas-mediated apoptosis of thyrocytes in this con-
dition [10]. Circulating forms of Fas are commonly 
considered as a factor that inhibits membrane Fas 
mediated apoptosis. These originate from both pro-
teolytic cleavage from the transmembrane domain 
and direct mRNA transcription [9,22,24]. In our stu-
dy, circulating sFas levels were simultaneously in-
creased with TG and TPO antibodies in GD. Thus, 
sFas may play a role with these molecules in preven-
ting the Fas/FasL-mediated apoptosis of thyrocytes 
in GD. The local production of sFas by thyrocytes, 
its regulation by cytokines, and its increased serum 
levels in GD have been confi rmed. These studies 
suggest that sFas, by interfering with the Fas-FasL 
interaction, plays a role in the pathogenesis of GD 
[1,15,18,21].
Hiromatsu et al. has shown that in HT, a higher 
degree of apoptosis is more due to thyrocytes with a 
more intense Fas expression on follicular cells than 
infi ltrating lymphocytes [15]. The presence of apop-
tosis has also been reported in HT [16].
Recently, Giordano et al. reported the constituti-
ve expression of FasL in normal and HT thyrocytes, 
indicating that they contribute to the development of 
clinical hypothyroidism [12]. FasL was initially re-
ported to be expressed in activated T cells and NK 
cells [13,18]. Moreover, taking into account the high 
cytotoxic capacity of a TPO antibody, a positive 
correlation between sFas and TPO antibodies in HT 
patients suggest that increased sFas may refl ect the 
intensity of the immune-involved destruction of the 
thyroid follicular cells.
Andrikoula et al. concluded that increased sFas 
in multinodular goiter may indicate an increased ex-
pression of alternatively spliced Fas mRNA variants 
and decreased expression of cell surface protein. This 
may enhance thyroid cell proliferation by protecting 
thyroid cells from Fas-mediated apoptosis [2]. A si-
milar observation was seen in our study. This indica-
tes that sFas can play a vital role in the pathogenesis 
of NG. sFas simultaneously increases with TG anti-
bodies in patients with goiter, showing unbalanced 
apoptosis and increased thyroid cell proliferation.
The functions of Fas have not yet been fully elu-
cidated, but there are several investigations sugges-
ting roles of both sFas and FasL in cancer progressi-
on. More recently, it has been reported that some tu-
mor cells, including those of epithelial origin, express 
FasL [1,4,7,21,27]. Several studies have demonstra-
ted high concentration of soluble Fas in large tumors 
in patients with ovarian cancer, cancer of the corpus 
uteri, colorectal cancer, thyroid cancer and adenoma, 
and adrenocortical cancer [3,30].
Using immunohistochemistry and mRNA stu-
dies, Basolo et al. demonstrated that different thyroid 
tissue expressions of Fas and FasL are simultaneously 
upregulated in adenomas and in well-differentiated 
papillary and follicular carcinomas. In contrast, Fas is 
suppressed, and FasL is strongly reduced in the most 
aggressive histological variants [4]. In our study, we 
observed that thyroid cancer patients had higher leve-
ls of sFas in lower levels FasL than patients with NG 
and AITD.
 Summary. Our study demonstrate that circula-
ting sFas and FasL concentrations are increased in 
Table 3 
Soluble Fas/ Fas ligand
† Variable Area under the curve pvalue 95% CI
Lower Upper
Soluble Fas 0.856 0.0001 0.712 1.000
Fas ligand 0.801 0.002 0.647 0.956
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patients with AITD, especially those with GD. This 
indicates enhanced thyroid cell proliferation by pro-
tecting against thyroid cell from Fas-mediated apop-
tosis. However, in contrast to GD, decreased sFas in 
HT increased FasL, indicate destruction of thyrocytes. 
In cases of thyroid NG, sFas may provide a key pro-
tective signal that helps the cells to avoid apoptosis 
in a hostile environment. Further studies with larger 
numbers of patients that evaluate the posttherapeutic 
changes in the levels of these molecules may provide 
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